#Japan #Tokyo #Ortho Corporation #Treg Cells #Immunoprotein IMP26

The Emergence of Regulatory T-Cell Research

Ortho Corporation, based in Minato-ku, Tokyo, has recently released a new handbook titled "Immunoprotein Handbook II," which consolidates the latest research findings related to immunity, with a particular focus on regulatory T-cells (Tregs). This publication comes at a time when Tregs are gaining global attention, especially in light of their significance in the upcoming 2025 Nobel Prize in Physiology or Medicine.

Highlighting Regulatory T-Cells (Tregs)

Tregs play a crucial role in modulating the activity of immune cells, ensuring that the immune system functions correctly. The expanding research on Tregs is promising, as it has the potential to uncover mechanisms behind various diseases, including allergies, autoimmune conditions, and cancer. Thus, understanding Tregs could pave the way for developing innovative therapies.

Research on Immunoprotein and Tregs

The "Immunoprotein Handbook II" features contributions from leading experts in the field, including Honorary Professor Yoshikawa Yasunobu from Kyushu University, Professor Suzuki Katsuhiko from Waseda University, and Assistant Professor Tanabe Hajime from Meikai University's School of Dentistry. Their collective work sheds light on recent breakthroughs regarding the relationship between immunoprotein, a food material, and immune balance.

A critical finding shared in the handbook arises from foundational research conducted on mice. In experiments, mice supplemented with immunoprotein exhibited elevated expressions of Tregs compared to those receiving standard protein. These results suggest that immunoprotein may influence the balance between Tregs and Th17 cells, indicating a promising avenue for future research.

Data on Conditioning for Athletes

In addition to the foundational research, the handbook also discusses clinical trial data involving human subjects. One study published in the international medical journal "Biomedicines" examined the effects of immunoprotein on runners during intense physical activity. The results showed that those who consistently consumed immunoprotein experienced temporary changes in kidney function—measured through urine concentration—and exhibited variations in inflammatory cytokines like TNF-α, as well as damage markers in the intestines (I-FABP).

Moreover, another study focused on university women's badminton players, investigating secretory IgA antibody (S-IgA) levels as an indicator of health. The findings indicated that the group supplementing with immunoprotein tended to have a higher rate of S-IgA secretion and significantly fewer fluctuations in its secretion frequency compared to the standard protein group.

The Composition of Immunoprotein (IMP26)

Immunoprotein (IMP26) is formulated using HIT (Hyper-Immunization Technology), which harnesses maternal and child immunity principles. This innovative approach involves neutralizing 26 types of pathogens commonly affecting humans and administering them to dairy cows, allowing the resultant milk to serve as the essential ingredient.

Ortho Corporation remains committed to supporting athletes and health-conscious individuals with its immunoprotein offerings, especially as the spotlight on regulatory T-cell research intensifies due to the upcoming Nobel Prize consideration.

Overview of "Immunoprotein Handbook II"

• - Publisher: Ortho Corporation
• - Supervisors: Yoshikawa Yasunobu (Honorary Professor, Kyushu University), Suzuki Katsuhiko (Professor, Waseda University), Tanabe Hajime (Assistant Professor, Meikai University)
• - Contents: The latest research findings on immunoprotein IMP26, including studies on Treg cells, kidney function, anti-inflammatory effects, and IgA antibodies.

Company Overview

Founded in 1979, Ortho Corporation has dedicated nearly 45 years to developing health foods. The company proudly embraces its purpose: "To challenge the new possibilities of beauty and health with sincerity and integrity," and continues to collaborate with researchers, universities, and enterprises both domestically and internationally for ongoing development.

• - Company Name: Ortho Corporation
• - Address: 10th Floor, Palazzo Astec, 2-8-1 Higashi-Shinbashi, Minato-ku, Tokyo, 105-0021, Japan
• - Representative: Aoyama Kairyuki, CEO
• - Established: September 14, 1979
• - Capital: 100 million JPY
• - Business: Development, manufacturing, and sales of health foods and nutritional supplements (OEM and direct sales)
• - Website: Ortho Corporation